Juva Life Inc. (OTCQB:JUVAF) (CSE:JUVA) (FRANKFURT:4VV) announced the successful scale up of proprietary molecule, JUVA-041, from microgram quantity to 5 gram quantity.

"Novel compound Juva-041 has demonstrated potent anti-inflammatory properties in phenotypic assays of inflammation, and is now being scaled up to support pre-clinical studies," stated Doug Chloupek, CEO and founder of Juva. "Through Juva's proprietary platform, we have made significant developments identifying the method and mode of action behind cannabis' anecdotal therapeutic potential. This scale-up hurdle we have crossed allows us a straight shot for commercial development devoid of manufacturing obstacles. These studies are the next step in unlocking the hidden value of the cannabis plant. Many companies struggle to scale up at the speed that Juva has, we are very pleased to see our alternative approach to medicinal chemistry is proving to be our competitive advantage."

JUVA-041 is a small molecule isolated from cannabis identified by Juva Life's research team. As with previously announced JUVA-019, JUVA-041 inhibits key cytokines proven to be of clinical relevance in inflammation but does so with selectivity and increased potency. Through the identification of JUVA-041, the company now has demonstrated the efficiency of its discovery approach.

The scale up of JUVA-041 through the standard pharmaceutical stage gate process, from microgram quantities to 5 gram quantities, will enable researchers to continue to test efficacy and toxicity of the molecule in mouse models. JUVA-041 has a pending patent filed by Juva Life.

Beyond its clinical research programs, Juva also recently relaunched its WIRB-approved JuLi Registry study with the goal of cultivating one of the largest data sets on the medicinal applications of cannabis use to exist to date.

Photo by Tim Foster on Unsplash

Related News

Juva Life Launches Flōs, New Branded Cannabis Flower Product Line